90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 21
Radioimmunotherapy of interleukin-2Rα - Expressing adult T-cell leukemia with yttrium-90 - Labeled anti-Tac.
Times cited: 206